Novel taxanes

Abstract

Since their addition to paclitaxel in the oncologists' armamentarium in the early 1990s, several new taxane formulations have been developed. Besides docetaxel and nab-paclitaxel, new analogs with better therapeutic profiles are being investigated. The goals of this next generation of taxanes are to improve the toxicity profile and efficacy, and to overcome resistance patterns. Several new taxanes, including cabazitaxel, paclitaxel poliglumex, paclitaxel+endotag, and polymeric-micellar paclitaxel, have shown clinical efficacy. These chemotherapeutics are part of many ongoing phase II and III studies on various cancer types. In addition, there are immunotoxins that link key antibodies to mitotic spindle inhibitors (trastuzumab emtansine and brentuximab vedotin). Through this mechanism, novel formulations increase cytotoxicity, improve specificity, and create possibilities for drug enhancement.

Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends

“…Another agent — TPI‐287 , a taxane derivative that demonstrates the ability to stabilize microtubular structures — is currently in phase I clinical studies for the treatment of mild‐to‐moderate AD and some other disorders related to disruption of intracell transport processes . Available structures for drugs affecting Tau aggregation are presented in Figure .…”

Current Trends in the Development of Drugs for the Treatment of Alzheimer’s Disease and their Clinical Trials

“…Он способен стабилизировать структуру микротрубочек. В настоящее время проходит фаза I клинических исследований данного препарата для лечения пациентов с легкой и умеренной формами БА, а также некоторых других расстройств, связанных с нарушением внутриклеточного транспорта [90]. Структуры препаратов, влияющих на агрегацию тау, представлены на рисунке 6.…”

What Is the Role of Nanotechnology in Diagnosis and Treatment of Metastatic Breast Cancer? Promising Scenarios for the Near Future

“…Certainly, further large randomized trials are required to better clarify Nab-paclitaxel activity and optimal dosages in different subtypes of aggressive MBC, but Nab-paclitaxel has anticipated what we can expect from nanotechnology introduction in clinical practice, showing global improvements in both outcome and quality of life of MBC patients, allowing shorter infusion time, avoidance of steroid premedication, and potentially higher administered dosages [21,22]. Other forms of nanoformulated paclitaxel are in phase II/III trials [78]. A cationic liposomal paclitaxel (EndoTAG) has been designed to enhance binding to negatively charged endothelial cells in tumor blood vessels, with an increased clinical benefit rate for cationic liposomal paclitaxel plus paclitaxel, although a slight increase in grades 3-4 neutropenia was observed [28].…”

“…A phase II trial performed on 41 MBCs treated with 4 Journal of Nanomaterials 6 Journal of Nanomaterials Journal of Nanomaterials 7 polymeric-micellar paclitaxel as single agent has revealed an objective response rate significantly higher if compared with that obtained at the same dosage with Nab-paclitaxel [29]. Polymeric-micellar paclitaxel is approved in South Korea for use in MBC [78].…”